| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 161 | Method of production of urokinase | US3711377D | 1970-10-22 | US3711377A | 1973-01-16 | SLOANE N |
| UROKINASE IS EXTRACTED FROM HUMAN URINE BY PASSING THE VOIDED URINE DIRECTLY THROUGH AN ABSORBENT THAT IS PLACED IN A TRAY IN THE MALE URINAL. THE PASSAGE OF THE VOIDED URINE THROUGH THE ABSORBENT CONTAINED IN SUCH A FILTERING DEVICE IN THE URINAL ALLOWS THE DIRECT ABSORPTION OF THE ENZYME ACTIVATOR, UROKINASE, ONTO THE ABSORBENT WITHOUT COLLECTING BULK URINE; AND THE SYSTEM ALLOWS THE PASSAGE OF THE ABSORBED URINE (FREED OF ITS UROKINASE) OF FLOW DIRECTLY INTO THE SEWER SYSTEM. THE ABSORBENTS USED IN THIS SYSTEM ARE: FLORISIL, CHARCOAL, ALUMINUM OXIDE, DENATURED HUMAN PROTEINS EMBEDDED IN A SILASTIC MATRIX. THE UROKINASE IS SOLUBILIZED FROM THESE ABSORBENTS AND FURTHER PURIFIED. UROKINASE IS REMOVED FROM FLORISIL, CHARCOAL AND ALUMINUM OXIDE BY COLD WEAK ACID SATURATED WITH ETHYL METHYL KETONE. UROKINASE IS REMOVED FROM THE SILASTIC EMBEDDED ABSORBENTS, DENATURED HUMAN PROTEINS.
|
||||||
| 162 | Process for fractionally obtaining urokinase and blood coagulation accelerator in human urine | US3542646D | 1967-11-15 | US3542646A | 1970-11-24 | AOKI NOBUO; ASADA TOSHIO |
| 163 | Method of production of urokinase | US3477913D | 1967-10-31 | US3477913A | 1969-11-11 | SLOANE NATHAN H |
| 164 | Method of production of urokinase | US3477911D | 1967-03-22 | US3477911A | 1969-11-11 | SLOANE NATHAN H |
| 165 | Purification of urokinase | US26734063 | 1963-03-22 | US3256158A | 1966-06-14 | FRANCIS WHITE WILFRID |
| 166 | Urokinase-alpha plasminogen activator and methods of obtaining the same | US78865259 | 1959-01-23 | US2989440A | 1961-06-20 | SINGHER HERON O; LEO ZUCKERMAN |
| 167 | Mirac proteins | US15337283 | 2016-10-28 | US09994841B2 | 2018-06-12 | Jay M. Short; Hwai Wen Chang; Gerhard Frey |
| This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | ||||||
| 168 | Mirac proteins | US14483980 | 2014-09-11 | US09982252B2 | 2018-05-29 | Jay M. Short; Hwai Wen Chang; Gerhard Frey |
| This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | ||||||
| 169 | Mirac proteins | US14196950 | 2014-03-04 | US09637734B2 | 2017-05-02 | Jay M. Short; Hwai Wen Chang; Gerhard Frey |
| This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | ||||||
| 170 | REDUCTION OF EGFR THERAPEUTIC TOXICITY | US15280673 | 2016-09-29 | US20170106059A1 | 2017-04-20 | Jaime F. Modiano; Daniel Vallera; Antonella Borgatti |
| In certain embodiments, the present invention provides a method of treating a subject having a tumor that expresses EGFR and/or uPAR, even if at low levels. In certain embodiments, the present invention provides a method of preventing hemangiosarcoma (HSA) in a dog predisposed to developing HSA or angiosarcoma in a human predisposed to developing angiosarcoma. In certain embodiments, the present invention provides a method of preventing a hemangiosarcoma (HSA) in a dog that is positive for HSA by means of a blood test but negative by tumor imaging. | ||||||
| 171 | NORMALIZATION OF THE ENTEROHEPATIC CIRCULATION IN ANIMALS WITH A CHIMERIC HUMANIZED LIVER | US15394007 | 2016-12-29 | US20170105395A1 | 2017-04-20 | Markus Grompe; Willscott Naugler |
| Methods of normalizing bile acid production in a mouse engrafted with human hepatocytes by the administration of human FGF19 are disclosed. Also disclosed is a transgenic host animal, such as a mouse, that expresses human FGF19 that has normalized bile acid production when engrafted with human hepatocytes. | ||||||
| 172 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES | US15004790 | 2016-01-22 | US20160338960A1 | 2016-11-24 | William R. Freeman; Michael J. Sailor; Lingyun Cheng |
| This invention relates to devices, systems and methods for delivering preprogrammed quantities of an active ingredient to a biological system over time without the need for external power or electronics. | ||||||
| 173 | Mirac proteins | US13255676 | 2010-03-09 | US09464284B2 | 2016-10-11 | Jay M. Short; Hwai Wen Chang; Gerhard Frey |
| This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | ||||||
| 174 | INTEGRATED INFUSION CONTAINER | US15080210 | 2016-03-24 | US20160199259A1 | 2016-07-14 | Gi-Bum OH |
| The present invention relates to unitary bottle for injection, more particularly, to a unitary medicine bottle having an integral structure where a medicine container is easily connected with a plastic container including a solution at a completely sterilized state so that powdered, freeze-dried or liquid medicine is mixed with the solution with one touch for a short time. The unitary medicine bottle for injection according to the present invention comprises: a plastic container equipped with a coupling member connected with a medicine container at one end and a releasing member for releasing a liquid medicine to be at the other end; a protection cap integrally formed with the coupling member to accept the medicine container; and a flue needle which moves forward in a direction of the medicine container and perforates a stopper of the medicine container and is inserted in the coupling member connecting the plastic container with the medicine container. | ||||||
| 175 | METHODS AND COMPOSITIONS FOR MODULATING FGF23 LEVELS | US14949266 | 2015-11-23 | US20160144001A1 | 2016-05-26 | Douglas E. Vaughan; Mesut Eren; Aaron T. Place; Toshio Miyata |
| The present invention provides compositions, systems, and methods for treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) with a composition comprising: i) an agent that causes an increase in expression of urokinase plasminogen activator (uPA) and/or tissue plasminogen activator (tPA), ii) purified uPA, and/or purified tPA. | ||||||
| 176 | Gelatinase inhibitors and prodrugs | US14567480 | 2014-12-11 | US09321754B2 | 2016-04-26 | Mayland Chang; Shahriar Mobashery; Mijoon Lee |
| The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration. | ||||||
| 177 | Protease screening methods and proteases identified thereby | US13506845 | 2012-05-18 | US09290757B2 | 2016-03-22 | Edwin L. Madison |
| Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases. | ||||||
| 178 | TREATMENT FOR AIRWAY CAST OBSTRUCTION | US14649238 | 2013-12-05 | US20150322421A1 | 2015-11-12 | Carl W. WHITE; Livia A. VERESS |
| The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent. | ||||||
| 179 | DIAGNOSTIC MARKER FOR TREATMENT OF CEREBRAL ISCHEMIA | US14657777 | 2015-03-13 | US20150258193A1 | 2015-09-17 | Lawrence M. KAUVAR; Damir JANIGRO |
| Identification of candidates for treatment and treatment of subjects experiencing cerebral ischemia wherein the treatment employs a thrombolytic or thrombectomy agent and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are determined by testing the blood of a patient for total S-100B or for S-100BB as a marker of blood brain barrier integrity. | ||||||
| 180 | NORMALIZATION OF THE ENTEROHEPATIC CIRCULATION IN ANIMALS WITH A CHIMERIC HUMANIZED LIVER | US14529011 | 2014-10-30 | US20150128299A1 | 2015-05-07 | Markus Grompe; Willscott Naugler |
| Methods of normalizing bile acid production in a mouse engrafted with human hepatocytes by the administration of human FGF19 are disclosed. Also disclosed is a transgenic host animal, such as a mouse, that expresses human FGF19 that has normalized bile acid production when engrafted with human hepatocytes. | ||||||
QQ群二维码
意见反馈
意见反馈